Feature | December 09, 2013

ACC Helps Hospitals, Patients Avoid Readmissions

Navigator program brings team approach to meeting patient needs, reducing rehospitalization

December 9, 2013 — With increased penalties in effect for hospitals with excessive readmissions for heart attack and heart failure, the American College of Cardiology (ACC) is launching a program that applies a team approach to keeping patients at home and healthy after discharge.
 
The ACC created the Patient Navigator Program to support a team of caregivers at selected hospitals to help patients overcome challenges during their hospital stay and in the weeks following discharge when they are at most risk for readmission. Hospitals have been given funding to establish a program that supports a culture of patient-centered care that can potentially be implemented in other hospitals in the future. AstraZeneca is the founding sponsor of the ACC Patient Navigator Program.
 
“The ACC Patient Navigator Program will serve as a test for innovative, patient-centered solutions to address issues that impact patient health and patient readmissions,” said John Harold, M.D., MACC, and president, ACC. “These hospitals will serve as pioneers in a new approach to heart disease treatment and care that puts emphasis on meeting patients’ ongoing needs and helping patients make a seamless transition from the hospital to the home.”
 
The Centers for Medicare and Medicaid Services increased penalties beginning Oct. 1 for hospitals with excessive readmission rates for heart attack, heart failure and three other non-cardiac conditions within 30 days of discharge. Hospitals could lose up to 2 percent of related Medicare and Medicaid reimbursements, which is double the prior maximum penalty of 1 percent of Medicare payments. Beginning in 2014, the penalty will increase again to a maximum of 3 percent.
 
Nearly one in five patients hospitalized with heart attack and one in four patients hospitalized with heart failure are readmitted within 30 days of discharge, often for conditions seemingly unrelated to the original diagnosis. Readmissions can be related to issues like stresses while in the hospital, fragility on discharge, lack of understanding of discharge instructions and inability to carry out discharge instructions.
 
Out of 132 hospitals initially surveyed about the program, 120 expressed an interest in participating in the first phase of the ACC Patient Navigator Program. Eleven hospitals were chosen for a 2013 program launch, with an additional 24 hospitals slated to join the program by the end of 2015.
 
Listed below are the first 11 participating hospitals, which were chosen because of their commitment to quality demonstrated by participation in the National Cardiovascular Data Registry and Hospital to Home program:
  • Advocate Sherman Hospital, Elgin, Ill.
  • Christiana Care Health Services, Wilmington, Del.
  • Einstein Medical Center Philadelphia, Philadelphia
  • Indiana University Health Methodist Hospital, Indianapolis
  • MedStar Washington Hospital Center, Washington
  • Providence St. Vincent Medical Center, Portland, Ore.
  • Ronald Reagan UCLA Medical Center, Los Angeles
  • St. Mary’s Hospital, Waterbury, Conn.
  • Trident Health, Charleston, S.C.
  • Vanderbilt Heart and Vascular Institute, Nashville, Tenn.
  • WakeMed Health and Hospital, Raleigh, N.C.
 
For more information: www.cardiosource.org

Related Content

NCDR, ACC, JACC, American College of Cardiology, national trends, heart disease treatments, trends in cardiovascular care
News | Cath Lab| January 23, 2017
January 23, 2017 — Over 93 percent of heart attack patients are receiving stents within the guideline-recommended thr
University of Utah, Frank Sachse, heart failure, LVAD implantation, left ventricular assist device, biomarker, t-system

Two patients may seem equally sick based upon clinical measures, but differences in their heart physiology could predict who has the potential to recover from heart failure. A study carried out by scientists at the University of Utah finds that patients whose hearts have flattened t-tubules have a decreased chance of showing signs of recovery after implanting a mechanical heart pump. Ordinarily, t-tubules in the heart are long, thin, and rounded. Image courtesy of Frank Sachse.

News | Cardiac Diagnostics| January 17, 2017
Investigators at the University of Utah have identified distinct differences in the hearts of advanced heart failure...
Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable| January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers
Medtronic, CoreValve Evolut R TAVR system, U.S. IDE Study, TCT 2016
News | Heart Valve Technology| November 03, 2016
Medtronic plc unveiled new clinical data showing that patients treated with the self-expanding CoreValve Evolut R...
congenital heart patients, cardiac cath lab, anesthesia sedation practices, joint document, SCAI, SPA, CCAS
News | Congenital Heart| November 03, 2016
The Society for Cardiovascular Angiography and Interventions (SCAI), the Society for Pediatric Anesthesia (SPA) and the...
open-heart surgery, PCI, percutaneous coronary intervention, NOBLE trial, left main coronary artery disease, LMCAD, TCT 2016
News | Cardiovascular Surgery| November 03, 2016
Coronary artery bypass (CABG) surgery is the standard treatment for revascularization in patients with left main...
SENTINEL trial, transcatheter embolic protection, TCEP, TAVR, stroke, TCT 2016
News | Embolic Protection Devices| November 03, 2016
An international study has found that transcatheter cerebral embolic protection (TCEP) is safe, provides effective...
News | Drug-Eluting Balloons| November 03, 2016
The Spectranetics Corp. announced that it has submitted to the U.S. Food & Drug Administration (FDA) its Pre-Market...
RESPECT trial, Amplatzer PFO Occluder, St. Jude Medical, TCT 2016
News | Structural Heart Occluders| November 02, 2016
St. Jude Medical Inc. announced the long-term data from RESPECT, a landmark trial, during a First Report session at the...
Medtronic, Resolute Integrity DES, drug-eluting stent, BIO-RESORT study, TCT 2016
News | Stents Drug Eluting| November 02, 2016
Investigators recently unveiled clinical data from the independent BIO-RESORT study, representing the first all-comers...
Overlay Init